AbbVie Acquires Celsius Therapeutics and its IBD Portfolio for US$250 M.

AbbVie, a pharmaceutical company, has acquired Celsius Therapeutics for $250 million in order to strengthen its portfolio of treatments for inflammatory bowel disease (IBD). Through the acquisition, AbbVie will gain access to Celsius' investigational asset CEL383, which has completed Phase I clinical studies for the treatment of IBD. This acquisition comes just three months after AbbVie announced the acquisition of Landos Biopharma and its portfolio of inflammatory and autoimmune disease medicines. The takeover of Celsius will help AbbVie expand its IBD pipeline after the patent expiry of its blockbuster drug Humira. [Extracted from the article]